For the quarter ending 2026-03-31, RARE made $136,000K in revenue. -$185,000K in net income. Net profit margin of -136.03%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 136,000 | 207,279 | 159,933 | 166,496 |
| Cost of sales | 30,000 | 29,345 | 27,991 | 23,002 |
| Research and development | 187,000 | 203,280 | 216,212 | 164,736 |
| Selling, general and administrative | 88,000 | 87,937 | 86,620 | 86,646 |
| Total operating expenses | 305,000 | 320,562 | 330,823 | 274,384 |
| Loss from operations | -169,000 | -113,283 | -170,890 | -107,888 |
| Other income (expense) | - | -934 | -1,043 | 2,140 |
| Interest income | 6,000 | 6,512 | 5,863 | 5,794 |
| Change in fair value of equity investments | - | - | 678 | -9 |
| Non-cash interest expense on liabilities for sales of future royalties | 21,000 | 19,469 | 14,148 | 14,041 |
| Loss before income taxes | -184,000 | -127,686 | -179,540 | -114,004 |
| Provision for income taxes | 1,000 | 870 | 873 | 947 |
| Net loss | -185,000 | -128,556 | -180,413 | -114,951 |
| Basic EPS | -1.84 | -1.287 | -1.81 | -1.17 |
| Diluted EPS | -1.84 | -1.287 | -1.81 | -1.17 |
| Basic Average Shares | 100,600,000 | 99,879,608 | 99,771,297 | 98,460,445 |
| Diluted Average Shares | 100,600,000 | 99,879,608 | 99,771,297 | 98,460,445 |
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)